Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells (Treg). These Treg cells are a specialized subpopulation of T cells involved in suppressing certain immune responses and maintaining the body’s self-tolerance. Reductions in the number of Treg cells have been shown to drive a spectrum of autoimmune diseases and conversely, increasing Treg expansion may have clinical utility in reducing inflammation and improving disease outcomes.
“THE BEST WAY TO PREDICT THE FUTURE
IS TO CREATE IT.”
Alan Kay Chief Computer Scientist from Atari
Early preclinical data investigating the effects of ImmTOR in combination with a Treg-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing the percentage and durability of Treg expansion in the spleen. This supports the potential of ImmTOR in combination with Treg-selective IL-2 proteins to restore immunotolerance to autoantigens and forms the basis for this partnership. Although IL-2 has been an attractive target for autoimmune indications, overcoming its immunostimulatory activities, short half-life and anti-IL-2 antibody formation has been challenging. Building on recent advancements in the field, Selecta’s strong preliminary data suggest that ImmTOR in combination with Cyrus’ novel Treg-selective IL-2 protein agonist has the potential to unlock the value of this target and drive the development of a next-generation, best-in-class therapeutic with utility across a range of autoimmune indications.
PARTNERING WITH US ON